How did Boston Scientific perform financially in the second quarter of 2021 compared to the same period in 2020?

Boston Scientific demonstrated a strong recovery in Q2 2021, with net sales increasing by 53.6% to $3.077 billion compared to $2.003 billion in Q2 2020. This growth was primarily driven by the resumption of elective procedures that were postponed during the COVID-19 pandemic. The company also returned to profitability, reporting net income available to common stockholders of $172 million ($0.12 per diluted share) in Q2 2021, a significant improvement from a net loss of $153 million ($(0.11) per diluted share) in Q2 2020.

What were the key drivers of the gross profit margin improvement?

The gross profit margin increased to 69.3% in Q2 2021 from 60.5% in Q2 2020. This improvement was primarily attributed to higher sales volumes due to the recovery of procedures, a favorable product mix with higher-margin products contributing more to sales, and the prior year's impact of abnormal production variances related to COVID-19-induced manufacturing shutdowns. The company also noted that price declines on certain products and foreign currency fluctuations had a partial offsetting effect.

How are the company's recent acquisitions impacting its financial performance?

The acquisition of Preventice Solutions, Inc. in Q1 2021 is contributing to the Cardiac Rhythm Management segment's growth. The company also completed the acquisition of Farapulse, Inc. in August 2021, which is expected to complement its electrophysiology portfolio and drive future growth. These strategic acquisitions are part of Boston Scientific's ongoing strategy to expand its product offerings and market reach.

What significant charges or liabilities affected the company's reported net income?

The company recorded significant litigation-related net charges of $298 million in Q2 2021, primarily related to transvaginal surgical mesh products. This was due to increased settlement and litigation activity post-COVID-19. While these charges impacted reported net income, the company also benefited from contingent consideration net benefits totaling $85 million in Q2 2021, related to adjustments for prior acquisitions where milestone achievement probabilities were reduced.

BSX 10-Q Quarterly Report Q2 FY2021 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported strong financial results for the second quarter and first half of 2021, demonstrating a significant recovery from the COVID-19 pandemic's impact in the prior year. Net sales surged by 53.6% in Q2 2021 to $3.077 billion and by 28.2% in the first six months to $5.829 billion, driven by the resumption of elective procedures and robust operational growth across key segments like Cardiovascular and MedSurg. The company also saw substantial improvements in profitability, with gross profit margin expanding to 69.3% in Q2 2021, up from 60.5% in Q2 2020, attributed to higher sales volumes, favorable product mix, and operational efficiencies. Net income available to common stockholders turned positive at $172 million ($0.12 per diluted share) for Q2 2021, a significant rebound from a net loss of $153 million ($(0.11) per diluted share) in the prior year. The company's strategic acquisitions, including Preventice Solutions, are contributing to growth, and it anticipates further gains from the recent acquisition of Farapulse, Inc.

Financial Highlights

50 data points

Beta

Revenue

$3.08B

0.7% Gross Margin

Net Income

$186.00M

0.1% Net Margin

EPS (Diluted)

$0.12

Total Assets

$31.17B

Cash & Equivalents

$2.67B

Free Cash Flow

$537.00M

Financial Statements

Beta

Revenue	$3.08B
Cost of Revenue	$945.00M
Gross Profit	$2.13B
SG&A Expenses	$1.12B
Operating Expenses	$1.87B
Operating Income	$262.00M
Interest Expense	$86.00M
Net Income	$186.00M
EPS (Basic)	$0.12
EPS (Diluted)	$0.12
Shares Outstanding (Basic)	1.42B
Shares Outstanding (Diluted)	1.43B

Key Highlights

1Net sales for Q2 2021 reached $3.077 billion, a 53.6% increase year-over-year, driven by the recovery in elective procedures.
2Gross profit margin improved significantly to 69.3% in Q2 2021 from 60.5% in Q2 2020, reflecting better pricing, product mix, and operational efficiencies.
3The company returned to profitability, reporting net income available to common stockholders of $172 million ($0.12 per diluted share) in Q2 2021, compared to a net loss of $153 million ($(0.11) per diluted share) in Q2 2020.
4Acquisitions, such as Preventice Solutions, are contributing to growth, with additional inorganic growth expected from the recent acquisition of Farapulse, Inc.
5Strong operational sales growth was observed across multiple segments, including Endoscopy (+58.5%), Urology and Pelvic Health (+73.9%), and Electrophysiology (+85.8%) for Q2 2021.
6The company has $2.675 billion in cash and cash equivalents as of June 30, 2021, with substantial liquidity to fund operations and strategic initiatives.
7Significant litigation-related charges of $298 million were recorded in Q2 2021 primarily related to transvaginal surgical mesh products, impacting reported net income.

BOSTON SCIENTIFIC CORP Quarterly Report for Q2 Ended Jun 30, 2021

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions